Published in the Journal of the American Pharmacists Association, the study found a significant improvement in the blood pressure of T2DM patients who were counseled by a pharmacist.
Results from a long-term study conducted at the University of Alberta found that an intergrated team of physicians and pharmacists can better help manage blood pressure in patients suffering from type 2 diabetes mellitus (T2DM).
This study, published in the Journal of the American Pharmacists Association, was part of a bigger study evaluating blood pressure control in T2DM patients. While the bigger study found that including pharmacists on the care team improved the health status of T2DM patients, the authors wanted to pinpoint the exact influence of pharmacists in managing hypertension in these patients.
The study showed that 42% of patients who were included in the intervention group, and received counselling by pharmacists, were twice as likely to show improvements in their blood pressure compared with patients in the non-intervention group.
Read more on EurekAlert!: http://bit.ly/1fgXJwq
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More